Authored Content
With the first output of the Joint Clinical Assessment (JCA) process in the European Union (EU) now published, Avalere Health considers implications for global market access strategies.
New research highlights the market access risks faced by manufacturers who use less traditional outcome measures to demonstrate value of innovative hemato-oncology therapies.